This page shows the latest Donanemab news and features for those working in and with pharma, biotech and healthcare.
Drug demonstrated a 'significant' slowing of cognitive decline. Eli Lilly’s amyloid-targeting antibody donanemab has shown promise in the treatment of Alzheimer’s disease, sending its stocks soaring and renewing ... function’. In other measures,
Eli Lilly is developing an antibody drug against it – called donanemab – which has reached the phase 2 testing stage.
Its pipeline currently includes solanezumab for Alzheimer’s – which has already failed earlier phase 3 trials – along with two antibodies for the disease in mid-stage testing (donanemab and zagotenemab) and
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...